Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism

This study was designed to establish the mechanism responsible for the increased apolipoprotein (apo) A-II levels caused by the cholesteryl ester transfer protein inhibitor torcetrapib. Nineteen subjects with low HDL cholesterol (<40 mg/dl), nine of whom were also treated with 20 mg of atorvastat...

Full description

Bibliographic Details
Main Authors: Margaret E. Brousseau, John S. Millar, Margaret R. Diffenderfer, Chorthip Nartsupha, Bela F. Asztalos, Megan L. Wolfe, James P. Mancuso, Andres G. Digenio, Daniel J. Rader, Ernst J. Schaefer
Format: Article
Language:English
Published: Elsevier 2009-07-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520307926